Canadian LPs Deepen Their European Cannabis Push

August 21, 2026

Photo by Tama66 via Pixabay.

Flower that once fetched top dollar in Canadian dispensaries is now selling for less than a loonie per gram at the wholesale level, and that number tells you almost everything you need to know about why Canada's biggest licensed producers have quietly turned their attention overseas. Domestic adult-use margins have been ground down by years of oversupply and price competition, leaving companies that once built their entire growth story around the Canadian market searching for somewhere the economics still work.

Germany gave them exactly that. The country's Cannabis Act, known as CanG, took effect in April 2024 and set off a surge in medical cannabis prescriptions that domestic German cultivation, and the rest of Europe's growers, simply weren't positioned to fill. That gap has become the single biggest opportunity in the global cannabis trade right now, and Canadian LPs are moving fast to claim a share of it. August 2026 alone brought a cluster of moves that make the pattern impossible to ignore: Tilray pushed its global cultivation capacity higher on the strength of its Portugal and Quebec facilities, Organigram agreed to pay €250 million for Berlin's Sanity Group, and Aurora picked up Safari Flower Company to lock in EU GMP-certified supply. None of this is happening in isolation. Canadian exports to Europe roughly doubled between 2024 and 2025, landing around 240 tonnes, and every major player in the industry seems to be racing toward the same conclusion at the same time.

Tilray Bets Big on Portugal and Quebec

Photo by CRYSTALWEED cannabis via Unsplash.

Tilray's numbers give the clearest picture of how quickly this shift is happening. As of August 2026, the company had raised its global cultivation capacity from roughly 210 metric tonnes to about 275, and the bulk of that growth isn't coming from some new market experiment but from doubling down on two facilities it already knows well: its Quebec cultivation site and its EU-GMP-certified operation in Portugal, which ranks among the largest medical cannabis production facilities anywhere in Europe.

What makes this interesting operationally is how Tilray is now moving product between those two sites. Bulk cannabis grown in Quebec is being shipped directly to the Portugal facility, as well as to Tilray's Australian operations, specifically to feed the demand coming out of Germany, the UK and other EU medical markets. It's a supply chain built around Portugal as the European finishing and distribution point, with Canadian cultivation acting as the volume engine behind it.

In Germany itself, Tilray's Aphria RX facility is reportedly running at full capacity, and the company's newer ARX brand has seen strong early uptake among patients since launch. CEO Irwin Simon has been explicit about the ambition here, framing this expansion not as a defensive move to offset weak Canadian pricing but as a genuine push for global leadership in the cannabis industry. Whether that framing holds up long-term will depend on execution, but the capacity numbers back up the rhetoric for now.

Organigram's €250 Million Bet on Berlin

Photo by Mr Dr3igeteilt via Pexels.

Organigram's move into Germany didn't come through years of slow, organic market building. It came through a checkbook. Organigram Global, which counts British American Tobacco as a major backer, announced it's acquiring Berlin-based Sanity Group for €250 million, a deal expected to close in the second quarter of 2026 assuming it clears shareholder approval, regulatory review in both Canada and Germany, and financing conditions.

The logic behind paying that kind of premium becomes clearer once you understand what Sanity Group actually brings to the table. This isn't a cultivation asset. It's a company that has spent years building cannabis brands, distribution relationships and pharmacy connections across Germany, which by prescription volume is now Europe's largest cannabis market by a wide margin. For Organigram, buying that infrastructure outright means skipping the slow grind of establishing pharmacy relationships and brand recognition from scratch in a market where German patients and pharmacists already have preferred suppliers.

There's a broader signal here too. When a company backed by one of the world's largest tobacco firms is willing to pay €250 million for a Berlin cannabis brand and distribution platform, it tells you Canadian and international capital increasingly sees direct access to Germany's prescription pipeline as worth a real premium, not just a nice-to-have expansion market. Expect this kind of consolidation, buying local platforms rather than building them, to keep showing up as more Canadian LPs chase the same German prescription volume.

Canopy, Aurora and Curaleaf Chase the Same Prize

Canopy Growth, Aurora Cannabis and Curaleaf are all circling the same European prize, though each is approaching it from a different angle. Canopy's European business currently runs at about C$10 million a quarter, or roughly C$40 million annualized, and CEO Luc Mongeau has set a target of pushing that run rate to somewhere between C$100 million and C$150 million. The growth plan leans on an EU GMP-compliant supply chain feeding Germany, a return to inventory in Poland where Canopy says it's now the number three player by market share, and the company's first shipment into the UK this quarter.

Aurora is making a more deliberate pivot away from adult-use entirely, according to CFO Simona King, who has framed the strategy as chasing higher-margin regulated medical markets in Australia, Germany and Poland rather than competing in commoditized recreational categories. That strategy got a concrete boost on August 11, 2026, when Aurora acquired Safari Flower Company specifically to supply EU GMP-certified flower into Germany, Australia, Poland and the UK simultaneously.

Curaleaf, meanwhile, has been building out its own European medical footprint through acquisitions rather than partnerships. The company completed its full buyout of Germany's Four 20 Pharma on April 30, 2026, and has since launched the Four 20 brand into both the UK and Poland. Its Polish clinic network, previously known as Fitokan, has been rebranded as Curaleaf Centrum Medyczne, part of a footprint that now spans the UK, Germany, Portugal, Spain, Sweden and Canada. Even smaller players are getting in on it: High Tide entered the German market by acquiring Berlin retailer Remexian AG, another sign of how crowded this race has become.

Why Germany Is Pulling in Canadian Supply

Canadian cannabis exports to Europe more than doubled from 115 tonnes in 2024 to 240 tonnes in 2025, highlighting rapid growth in transatlantic cannabis trade.

Germany's Cannabis Act reshaped the medical cannabis landscape almost overnight when it took effect in April 2024, loosening prescribing rules in ways that triggered a rapid surge in patient demand. The problem, from a supply standpoint, is that neither Germany's domestic cultivation capacity nor the rest of Europe's growers were built to handle that kind of volume increase on short notice. Germany ended up importing nearly 200 tons of cannabis in 2025, and Canada was its single largest supplier by a comfortable margin.

That import appetite lines up with what's happening on the Canadian export side. Canadian cannabis exports to Europe reached roughly 240 tonnes in 2025, more than double the total from the year before. Part of that is demand pull from Germany, but part of it is also a push factor at home: domestic Canadian flower prices have fallen below CA$1 per gram in many wholesale transactions, squeezing margins so hard that export markets with pharmacy-grade pricing look far more attractive by comparison.

The regulatory hinge that makes all of this legally possible is EU GMP certification, the manufacturing standard that allows Canadian-grown product to move into pharmacy-based medical systems across Germany, Poland and the UK. Without that certification, none of this trade happens, regardless of how much capacity a Canadian LP builds. It's worth remembering, too, that cannabis law varies significantly by country within the EU, and licensing, import and prescribing requirements differ from one market to the next. Companies and consumers alike should confirm current rules in the specific jurisdiction they're dealing with rather than assuming what's permitted in Germany automatically applies in Poland, Portugal or the UK.

Pushing Back on the Narco State Narrative

Photo by Timelab via Unsplash.

Not every headline about Canadian cannabis exports to Europe has been favorable. A report from the Telegraph in the UK attempted to draw a line between legal, licensed Canadian cannabis shipments and broader concerns about European drug trafficking, framing the export growth as part of a narco state narrative around Canada's cannabis industry.

Industry outlet StratCann pushed back on that framing in July 2026, pointing out that there's no actual evidence connecting licensed, regulated Canadian exports to any increase in smuggling or illicit trafficking activity in Europe. The distinction matters because it's not a subtle one: licensed exports move through EU GMP-certified, fully tracked supply chains, with documentation and chain-of-custody requirements at every stage, from cultivation in Quebec or Portugal through to pharmacy shelves in Germany. That's a fundamentally different system from illicit trafficking routes, which by definition operate outside any regulatory tracking at all.

This kind of pushback matters more now than it would have a few years ago, simply because the legitimate medical export business has grown large enough to attract political attention on both sides of the Atlantic. As Canadian LPs keep scaling shipments into Germany, Poland and the UK, and as those numbers keep showing up in trade data, the industry has a real interest in making sure regulators and the public don't conflate a legal, tracked pharmaceutical supply chain with something else entirely. Getting that distinction right isn't just a PR concern, it's likely to shape how comfortable regulators in importing countries remain with letting Canadian volume keep growing.

Watch where the capital and the acquisitions are going, not where the press releases are dated from, and it's clear the center of gravity for Canadian cannabis producers has moved. Domestic adult-use, once the entire reason these companies existed, has become the segment everyone is trying to grow out of, while European medical markets with pharmacy-grade pricing have become the segment everyone is trying to grow into.

Germany will remain the market that matters most for the foreseeable future, given its prescription volume and its role as the largest single destination for Canadian exports. But Poland and the UK are shaping up as the next real battlegrounds, and it's notable that it's largely the same handful of Canadian players, Canopy, Aurora, Curaleaf, Tilray, Organigram, showing up in each of those markets almost simultaneously.

If the pattern from Sanity Group, Safari Flower and Four 20 Pharma holds, expect the next wave of European expansion to keep coming through acquisitions of existing brands, clinics and distribution networks rather than through years of organic buildout. In a market moving this fast, buying a foothold beats building one from scratch, and the companies willing to pay for speed are the ones setting the pace for everyone else.